Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating the efficacy and safety of Efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antisynthetase Syndrome
• Dermatomyositis
• Idiopathic Inflammatory Myopathy
• Immune-mediated Necrotizing Myopathy
• Polymyositis

Drugs mentioned

• Efgartigimod PH20 SC (efgartigimod alfa)

Snippet

Sponsor: argenx | Conditions: Active Idiopathic Inflammatory Myopathy, Myositis | Phase 2, Phase 3 | Status: COMPLETED